Two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, according to results of a large international clinical trial led by researchers at Dana-Farber Cancer Institute. Pazopanib (Votrient) and sunitinib (Sutent), both recently approved as first-line treatments for advanced renal cell cancer, had similar benefits in delaying progression of the disease, but the safety profile and many measures of quality of life favored pazopanib, suggesting a potential shift in standard of care in metastatic kidney cancer. Read more here.
Study mentioned: Motzer RJ, et al. Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. N Engl J Med 2013; 369:722-731.
No comments:
Post a Comment